These findings suggest that targeting CTLA-4 in the intact TME of tumor fragments can increase the number of TILs that respond to tumors, thereby improving clinical outcomes of TIL-based applied cell therapy (ACT) in OC [450]. Here, CTLA4 is linked to neoplasm.